Ossianix Announces Strategic Research Collaboration with Lundbeck

10-01-2014 Business Wire HealthComments (0)

LundbeckOssianixPharmaceutical

Ossianix, Inc. today announced a strategic research collaboration with Lundbeck A/S. The collaboration uses Ossianix’s innovative single domain antibody platform based on the shark VNAR structure.

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top